The most frequently reported adverse events in clinical trials included injection site reactions (erythema, pruritus, pain, irritation, bruising) occurring in 30-40% of patients, typically mild to moderate and often decreasing over time with continued treatment, manageable with proper injection technique and site rotation
L-carnitine regulated Nrf2/Keap1 activation in vitro and in vivo and protected oxidized fish oil-induced inflammation response by inhibiting the NF-B signaling pathway in Rhynchocypris Lagowski Dybowski
Jardiance (empagliflozin), an SGLT2 inhibitor, and Mounjaro (tirzepatide), a dual GIP/GLP-1 receptor agonist, represent two fundamentally different approaches to treating type 2 diabetes
This is a retrospective study and not a randomized controlled trial, so there may be confounding factors affecting which patients were given GLP-1 prescriptions rather than other treatments, despite trial controls
Elyada E, Pribluda A, Goldstein RE, Morgenstern Y, Brachya G, Cojocaru G, Snir-Alkalay I, Burstain I, Haffner-Krausz R, Jung S, et al
